These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8882330)

  • 1. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
    Biberfeld G; Thorstensson R; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):443-6. PubMed ID: 8882330
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization.
    Biberfield G; Putkonen P; Thorstensson R; Norrby E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1511-3. PubMed ID: 1466992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.
    Cranage MP; Polyanskaya N; McBride B; Cook N; Ashworth LA; Dennis M; Baskerville A; Greenaway PJ; Corcoran T; Kitchin P
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):13-22. PubMed ID: 8427714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate vaccines protect macaques against primate immunodeficiency viruses.
    Stott J; Hu SL; Almond N
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early helper T-cell dysfunction in simian immunodeficiency virus but not in human immunodeficiency virus type-2-infected macaques.
    Dittmer U; Lüke W; Stahl-Hennig C; Coulibaly C; Petry H; Bodemer W; Hunsmann G; Voss G
    J Med Primatol; 1994 Jul; 23(5):298-303. PubMed ID: 7869358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus.
    Cranage MP; Baskerville A; Ashworth LA; Dennis M; Cook N; Sharpe S; Farrar G; Rose J; Kitchin PA; Greenaway PJ
    Lancet; 1992 Feb; 339(8788):273-4. PubMed ID: 1346285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine.
    Putkonen P; Walther L; Zhang YJ; Li SL; Nilsson C; Albert J; Biberfeld P; Thorstensson R; Biberfeld G
    Nat Med; 1995 Sep; 1(9):914-8. PubMed ID: 7585217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells.
    Johnson PR; Montefiori DC; Goldstein S; Hamm TE; Zhou J; Kitov S; Haigwood NL; Misher L; London WT; Gerin JL
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1501-5. PubMed ID: 1466990
    [No Abstract]   [Full Text] [Related]  

  • 13. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
    Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
    J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.
    Hirsch VM; Goldstein S; Hynes NA; Elkins WR; London WT; Zack PM; Montefiori D; Johnson PR
    J Infect Dis; 1994 Jul; 170(1):51-9. PubMed ID: 8014520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS vaccine developments.
    Osterhaus A; de Vries P; Heeney J
    Nature; 1992 Feb; 355(6362):684-5. PubMed ID: 1741054
    [No Abstract]   [Full Text] [Related]  

  • 17. AIDS vaccine developments.
    Cranage MP; Ashworth LA; Greenaway PJ; Murphey-Corb M; Desrosiers RC
    Nature; 1992 Feb; 355(6362):685-6. PubMed ID: 1741055
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using SHIVs to develop an anti-HIV-1 live-attenuated vaccine.
    Kuwata T; Miura T; Hayami M
    Trends Microbiol; 2001 Oct; 9(10):475-80. PubMed ID: 11597447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.